Novartis awarded 55 mln usd vaccine development contract from US govt

|

novartis BASEL (AFX) - Novartis AG said it has received a contract from the US health department worth approximately 55 mln usd to further develop a novel antigen technology that could extend vaccine supplies in a pandemic outbreak.

The contract supports the company's efforts to develop and manufacture its MF59 adjuvant in the US, the Basel-based drug maker said.

An adjuvant is a substance added to a vaccine to enhance the body's immune response to the vaccine's active constituent.

source - AFX